Novo Nordisk (NVO)
(Real Time Quote from BATS)
$127.09 USD
+1.30 (1.03%)
Updated Apr 26, 2024 03:11 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Novo Nordisk (NVO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$151.40 | $163.00 | $139.00 | 20.36% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Novo Nordisk comes to $151.40. The forecasts range from a low of $139.00 to a high of $163.00. The average price target represents an increase of 20.36% from the last closing price of $125.79.
Analyst Price Targets (5 )
Broker Rating
Novo Nordisk currently has an average brokerage recommendation (ABR) of 1.54 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.58 a month ago based on 13 recommendations.
Of the 14 recommendations deriving the current ABR, 10 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 71.43% and 7.14% of all recommendations. A month ago, Strong Buy made up 69.23%, while Buy represented 7.69%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 9 | 9 | 9 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.54 | 1.54 | 1.58 | 1.58 | 1.58 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/12/2024 | BMO Capital Markets | Evan Seigerman | Not Available | Strong Buy |
3/8/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
11/12/2023 | Guggenheim Securities | Seamus Fernandez | Not Available | Strong Buy |
11/1/2023 | Exane BNP Paribas | Richard Parkes | Not Available | Hold |
10/2/2023 | Argus Research Corp. | John M Eade | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.54 |
ABR (Last week) | 1.54 |
# of Recs in ABR | 14 |
Average Target Price | $151.40 |
LT Growth Rate | 18.00% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 198 of 252 |
Current Quarter EPS Est: | 0.77 |